Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae
Sarah Christina Jane Jorgensen(Eugene Applebaum College of Pharmacy and Health Sciences), Michael J. Rybak(Eugene Applebaum College of Pharmacy and Health Sciences)
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
February 10, 2018
Cited by 85
Related Papers
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
|Clinical Infectious Diseases|2011|4.2k
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
|American Journal of Health-System Pharmacy|2008|1.8k
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary
|Clinical Infectious Diseases|2011|1.6k
Therapeutic Monitoring of Vancomycin in Adults
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2009|399
Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant <i>Acinetobacter baumannii</i> infections
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2023|50